Daratumumab 1.8g/15ml solution for injection vials
NHS hospitals in England used £521,002,512 of indicative cost of Daratumumab 1.8g/15ml solution for injection vials in the 12 months to July 2026, about 2.0% of all hospital medicines spend. That is up 7.6% on the previous 12 months.
Indicative cost · 12 months
Quantity (VMP units) · 12 months
Share of hospital medicines spend
Figure 1. Daratumumab 1.8g/15ml solution for injection vials: NHS hospital indicative cost by month (£ millions)
Source: NHSBSA Secondary Care Medicines Data, to July 2026
Cost is indicative — actual hospital medicine prices are commercially confidential, so these figures are estimated from list prices. See methodology.
NHS trusts using Daratumumab 1.8g/15ml solution for injection vials most
By indicative cost over the 12 months to July 2026.
| NHS trust | Indicative cost (12 months) |
|---|---|
| United Lincolnshire Hospitals Nhs Trust | £12,342,240 |
| Western Sussex Hospitals Nhs Found Trust | £12,057,120 |
| Southend Univ Hosp Nhs Foundation Trust | £11,841,120 |
| University College London Foundation Tr | £10,152,000 |
| Barts Health Nhs Trust | £9,858,240 |
| Derby Teaching Hospitals Nhs Found Trust | £9,404,640 |
| Colchester Hospital University Nhs Ft | £9,361,440 |
| Norfolk & Norwich University Hpl Nhs Trt | £9,339,840 |
| University Hpls North Midlands Nhs Trust | £8,462,880 |
| University Hpls Of Leicester Nhs Trust | £8,424,000 |
The primary-care picture
No confident match to a community-dispensed medicine was found for this product, so no primary-care comparison is shown. SCMD products are recorded at product level, which does not always map cleanly to a BNF substance.